Glwl-01 (DrugBank: -)
1 disease| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 193 | プラダー・ウィリ症候群 | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03274856 (ClinicalTrials.gov) | February 20, 2018 | 5/9/2017 | A Study of GLWL-01 in Patients With Prader-Willi Syndrome | A Phase 2 Study to Evaluate Efficacy, Safety, and Pharmacokinetics of GLWL-01 in the Treatment of Patients With Prader-Willi Syndrome | Prader-Willi Syndrome | Drug: GLWL-01;Drug: Placebo | GLWL Research Inc. | NULL | Completed | 16 Years | 65 Years | All | 19 | Phase 2 | United States;Canada |